Skip to main content
. 2018 Dec 13;7(24):e010274. doi: 10.1161/JAHA.118.010274

Table 1.

Baseline Characteristics

All (N=465) Alive (n=410) Dead (n=55) P Value
Age at the beginning of study, y 37±14 35±13 47±15 <0.001
Men, No. (%) 223 (48) 186 (45) 37 (67) 0.004
Body mass index, kg/m2 27±6 27±6 28±6 0.168
Body surface area, m2 1.9±0.3 1.8±0.2 1.9±0.2 0.475
Age at TOF repair, y 5 (3–10) 5 (2–8) 14 (5–34) <0.001
Prior palliative shunt, No. (%) 181 (39) 148 (37) 33 (60) 0.004
Comorbidities, No. (%)
Atrial fibrillation 118 (25) 82 (20) 36 (55) <0.001
Atrial flutter/tachycardia 100 (22) 79 (19) 21 (38) 0.002
Hypertension 125 (27) 102 (25) 23 (42) 0.004
Hyperlipidemia 193 (42) 162 (40) 31 (56) 0.060
Coronary artery disease 57 (12) 38 (9) 19 (35) 0.011
Current or prior smoker 93 (20) 77 (18) 18 (32) 0.064
Diabetes mellitus 72 (16) 59 (15) 13 (23) 0.117
Sleep apnea 130 (28) 109 (27) 21 (38) 0.155
Prior stroke 41 (9) 33 (8) 8 (15) 0.943
NYHA class III/IV 73 (16) 59 (15) 14 (25) 0.002
Down syndrome 9 (2) 8 (2.0) 1 (1.8) 0.914
22q11 deletion 7 (1.5) 6 (1.5) 1 (1.8) 0.943
Laboratory tests
Hemoglobin, g/dL 14.1±2.5 14.0±2.6 13.4±2.1 0.018
Creatinine, mg/dL 1.0±0.3 0.9±0.2 1.3±0.5 <0.001
NT‐proBNP, pg/mL 255 (123–720) 223 (112–813) 313 (146–481) 0.348
Medications, No. (%)
Diuretics 84 (18) 63 (15) 21 (38) <0.001
 β‐Blockers 106 (23) 76 (19) 30 (54) <0.001
Calcium channel blockers 59 (13) 39 (10) 20 (36) <0.001
RAAS antagonist 87 (19) 68 (17) 19 (34) 0.002
Warfarin 41 (9) 29 (7) 12 (21) 0.001
Direct oral anticoagulants 3 (0.7) 2 (0.5) 1 (0.7) 0.330
Aspirin 116 (25) 97 (24) 19 (33) 0.118

Values are expressed as mean±SD or median (interquartile range) unless otherwise indicated. NT‐proBNP indicates N‐terminal pro b‐type natriuretic peptide; NYHA, New York Heart Association; RAAS, renin‐angiotensin‐aldosterone system; TOF, tetralogy of Fallot.